Safety pharmacology of acute psilocybin administration in healthy participants

• DOI: 10.1016/j.nsa.2024.104060
• Publication Date: 2024-03-16T06:19:51Z
• Authors: Isabelle Straumann; Friederike Holze; Anna M. Becker; Laura Ley; Nepomuk Halter; Matthias E. Liechti
• Keywords: Psilocybin; Safety pharmacology; Clinical Pharmacology

Psilocybin is being studied for its therapeutic potential in various mental health disorders, such as depression, anxiety, and addiction. Initial studies suggested that psilocybin generally safe when used under controlled conditions, but more research needed to better understand safety profile. We report pharmacology data from a pooled analysis of three randomized crossover included 85 healthy participants 113 single-dose administrations psilocybin. Single oral doses 15 mg, 20 25 30 mg dihydrate. investigated subjective effects, blood pressure, heart rate, body temperature, acute subacute adverse reports flashbacks, liver kidney function before after the studies. The 20, 25, produced stronger effects than dose. at all induced higher "good drug effects" "bad effects." Only increased anxiety. elevated autonomic only moderately. Tachycardia (>100 beats/min) was observed with 7% administrations. Body temperature >38° reached 7%, 9%, 17%, 32% 15, doses, respectively. Kidney parameters were unaltered end study. Five (6%) reported transient flashback phenomena. No serious reactions occurred. These findings suggest single administration regard psychological physical harm setting.